STOCK TITAN

[SCHEDULE 13G/A] Pasithea Therapeutics Corp. Warrants SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Pasithea Therapeutics reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclose beneficial ownership of 826,145 shares of common stock through Series C and Series D warrants, representing 9.9% of the outstanding class. The Warrants include a contractual limitation that prevents exercise to the extent such exercise would raise ownership above 9.99%. Heights Capital, as investment manager to CVI Investments, may be deemed to have shared voting and dispositive power over the reported position, while neither reporting person claims sole voting or dispositive power. The filing also references 7,443,577 shares outstanding (excluding shares underlying the warrants) as reported in the company's quarterly report.

Pasithea Therapeutics i soggetti segnalanti CVI Investments, Inc. e Heights Capital Management, Inc. dichiarano la titolarità beneficiaria di 826,145 azioni ordinarie tramite warrant di Serie C e Serie D, pari a 9.9% della classe in circolazione. I warrant prevedono un limite contrattuale che impedisce l'esercizio nella misura in cui l'esercizio stesso porterebbe la partecipazione oltre il 9.99%. Heights Capital, in qualità di gestore degli investimenti per CVI Investments, può essere considerata titolare di poteri condivisi di voto e di disposizione sulla posizione segnalata, mentre nessuno dei soggetti segnalanti rivendica il potere esclusivo di voto o di disposizione. Il deposito fa inoltre riferimento a 7,443,577 azioni in circolazione (escluse le azioni sottostanti i warrant) come riportato nel rapporto trimestrale della società.

Pasithea Therapeutics las personas que informan, CVI Investments, Inc. y Heights Capital Management, Inc., declaran la propiedad beneficiaria de 826,145 acciones ordinarias mediante warrants de Serie C y Serie D, que representan el 9.9% de la clase en circulación. Los warrants incluyen una limitación contractual que impide el ejercicio en la medida en que dicho ejercicio aumentara la participación por encima del 9.99%. Heights Capital, como gestor de inversiones de CVI Investments, puede considerarse que tiene poderes compartidos de voto y de disposición sobre la posición comunicada, mientras que ninguno de los informantes reclama poder exclusivo de voto o de disposición. La presentación también hace referencia a 7,443,577 acciones en circulación (excluyendo las acciones subyacentes a los warrants) según se informó en el informe trimestral de la compañía.

Pasithea Therapeutics 신고인인 CVI Investments, Inc. 및 Heights Capital Management, Inc.는 C·D 시리즈 워런트를 통해 보통주 826,145주를 실질적으로 보유하고 있으며 이는 발행주식수의 9.9%에 해당한다고 공시합니다. 해당 워런트에는 워런트 행사를 통해 보유지분이 9.99%를 초과하는 경우 행사를 제한하는 계약상 조항이 포함되어 있습니다. Heights Capital은 CVI Investments의 투자운용사로서 보고된 보유지분에 대해 의결권 및 처분권을 공유하는 것으로 간주될 수 있으나, 어느 신고인도 단독 의결권 또는 처분권을 주장하지는 않습니다. 또한 제출서류에는 회사 분기보고서에 기재된 바와 같이 워런트 기초 주식을 제외한 발행주식수 7,443,577주도 언급되어 있습니다.

Pasithea Therapeutics les personnes déclarantes CVI Investments, Inc. et Heights Capital Management, Inc. déclarent la propriété bénéficiaire de 826,145 actions ordinaires via des warrants de série C et D, représentant 9.9% de la catégorie en circulation. Les warrants comportent une clause contractuelle qui empêche l'exercice dans la mesure où cet exercice porterait la participation au‑delà de 9.99%. Heights Capital, en tant que gestionnaire d'investissement de CVI Investments, peut être considéré comme ayant des pouvoirs partagés de vote et de disposition sur la position déclarée, tandis qu'aucune des personnes déclarantes ne revendique un pouvoir de vote ou de disposition exclusif. Le dépôt fait également référence à 7,443,577 actions en circulation (hors actions sous‑jacentes aux warrants) comme indiqué dans le rapport trimestriel de la société.

Pasithea Therapeutics melden die berichtspflichtigen Personen CVI Investments, Inc. und Heights Capital Management, Inc. den begünstigten Besitz von 826,145 Stammaktien durch Serie-C- und Serie-D-Warrants, was 9,9% der ausstehenden Klasse entspricht. Die Warrants enthalten eine vertragliche Beschränkung, die die Ausübung verhindert, soweit dadurch die Beteiligung über 9.99% steigen würde. Heights Capital kann als Investmentmanager von CVI Investments als Inhaber gemeinsamer Stimm- und Verfügungsrechte über die gemeldete Position angesehen werden, während keiner der meldenden Personen alleinige Stimm- oder Verfügungsgewalt beansprucht. Die Einreichung verweist außerdem auf 7,443,577 ausstehende Aktien (ohne die unter den Warrants liegenden Aktien), wie im Quartalsbericht des Unternehmens angegeben.

Positive
  • Transparent disclosure of a material position: the filing reports 826,145 shares via warrants, equal to 9.9% of the class
  • Exercise cap explicitly limits conversion above 9.99%, clarifying that immediate control changes are constrained
  • Investment manager relationship is disclosed, explaining the basis for shared voting and dispositive power
Negative
  • Significant near-10% position could represent potential future dilution if warrants are exercised up to the permitted threshold
  • No sole voting or dispositive power reported, which may limit the reporting persons' ability to unilaterally influence governance

Insights

TL;DR: A near-10% warrant position disclosed; exercise capped below control threshold; investment manager may exercise shared authority.

The filing shows CVI Investments and Heights Capital hold 826,145 shares beneficially via Series C and D warrants, equal to 9.9% of the company on a reported outstanding base of 7,443,577 shares (excluding warrants). The explicit 9.99% exercise cap limits immediate conversion-driven control shifts. Disclosure of shared voting and dispositive power via Heights as investment manager is material for ownership transparency and potential future dilution analysis.

TL;DR: Material ownership disclosed without assertion of control; governance implications hinge on warrant exercise limits and manager authority.

The report clarifies that neither reporting person claims sole voting or dispositive power, instead reporting shared voting and dispositive power over the 826,145 warrant-linked shares. The limitation preventing exercise above 9.99% reduces the likelihood of an immediate change in control but makes the position a significant minority stake that warrants monitoring for future conversions or coordination among holders.

Pasithea Therapeutics i soggetti segnalanti CVI Investments, Inc. e Heights Capital Management, Inc. dichiarano la titolarità beneficiaria di 826,145 azioni ordinarie tramite warrant di Serie C e Serie D, pari a 9.9% della classe in circolazione. I warrant prevedono un limite contrattuale che impedisce l'esercizio nella misura in cui l'esercizio stesso porterebbe la partecipazione oltre il 9.99%. Heights Capital, in qualità di gestore degli investimenti per CVI Investments, può essere considerata titolare di poteri condivisi di voto e di disposizione sulla posizione segnalata, mentre nessuno dei soggetti segnalanti rivendica il potere esclusivo di voto o di disposizione. Il deposito fa inoltre riferimento a 7,443,577 azioni in circolazione (escluse le azioni sottostanti i warrant) come riportato nel rapporto trimestrale della società.

Pasithea Therapeutics las personas que informan, CVI Investments, Inc. y Heights Capital Management, Inc., declaran la propiedad beneficiaria de 826,145 acciones ordinarias mediante warrants de Serie C y Serie D, que representan el 9.9% de la clase en circulación. Los warrants incluyen una limitación contractual que impide el ejercicio en la medida en que dicho ejercicio aumentara la participación por encima del 9.99%. Heights Capital, como gestor de inversiones de CVI Investments, puede considerarse que tiene poderes compartidos de voto y de disposición sobre la posición comunicada, mientras que ninguno de los informantes reclama poder exclusivo de voto o de disposición. La presentación también hace referencia a 7,443,577 acciones en circulación (excluyendo las acciones subyacentes a los warrants) según se informó en el informe trimestral de la compañía.

Pasithea Therapeutics 신고인인 CVI Investments, Inc. 및 Heights Capital Management, Inc.는 C·D 시리즈 워런트를 통해 보통주 826,145주를 실질적으로 보유하고 있으며 이는 발행주식수의 9.9%에 해당한다고 공시합니다. 해당 워런트에는 워런트 행사를 통해 보유지분이 9.99%를 초과하는 경우 행사를 제한하는 계약상 조항이 포함되어 있습니다. Heights Capital은 CVI Investments의 투자운용사로서 보고된 보유지분에 대해 의결권 및 처분권을 공유하는 것으로 간주될 수 있으나, 어느 신고인도 단독 의결권 또는 처분권을 주장하지는 않습니다. 또한 제출서류에는 회사 분기보고서에 기재된 바와 같이 워런트 기초 주식을 제외한 발행주식수 7,443,577주도 언급되어 있습니다.

Pasithea Therapeutics les personnes déclarantes CVI Investments, Inc. et Heights Capital Management, Inc. déclarent la propriété bénéficiaire de 826,145 actions ordinaires via des warrants de série C et D, représentant 9.9% de la catégorie en circulation. Les warrants comportent une clause contractuelle qui empêche l'exercice dans la mesure où cet exercice porterait la participation au‑delà de 9.99%. Heights Capital, en tant que gestionnaire d'investissement de CVI Investments, peut être considéré comme ayant des pouvoirs partagés de vote et de disposition sur la position déclarée, tandis qu'aucune des personnes déclarantes ne revendique un pouvoir de vote ou de disposition exclusif. Le dépôt fait également référence à 7,443,577 actions en circulation (hors actions sous‑jacentes aux warrants) comme indiqué dans le rapport trimestriel de la société.

Pasithea Therapeutics melden die berichtspflichtigen Personen CVI Investments, Inc. und Heights Capital Management, Inc. den begünstigten Besitz von 826,145 Stammaktien durch Serie-C- und Serie-D-Warrants, was 9,9% der ausstehenden Klasse entspricht. Die Warrants enthalten eine vertragliche Beschränkung, die die Ausübung verhindert, soweit dadurch die Beteiligung über 9.99% steigen würde. Heights Capital kann als Investmentmanager von CVI Investments als Inhaber gemeinsamer Stimm- und Verfügungsrechte über die gemeldete Position angesehen werden, während keiner der meldenden Personen alleinige Stimm- oder Verfügungsgewalt beansprucht. Die Einreichung verweist außerdem auf 7,443,577 ausstehende Aktien (ohne die unter den Warrants liegenden Aktien), wie im Quartalsbericht des Unternehmens angegeben.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G




Comment for Type of Reporting Person: With respect to Row 6 and Row 8 above, Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.


SCHEDULE 13G



CVI Investments, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary of Heights Capital Management, Inc.
Date:08/12/2025
Heights Capital Management, Inc.
Signature:/s/ Sarah Travis
Name/Title:Sarah Travis, Assistant General Counsel and Assistant Secretary
Date:08/12/2025

Comments accompanying signature: Heights Capital Management, Inc. serves as authorized agent of CVI Investments, Inc. pursuant to a Limited Power of Attorney, a copy of which was previously filed.
Exhibit Information

EXHIBIT INDEX EXHIBIT DESCRIPTION ________________ I Limited Power of Attorney* II Joint Filing Agreement* * Previously filed

FAQ

What stake do CVI Investments and Heights Capital report in Pasithea (KTTAW)?

They report beneficial ownership of 826,145 shares via Series C and Series D warrants, representing 9.9% of the class.

Are the warrants exercisable into Pasithea (KTTAW) common shares without restriction?

No. The Warrants are not exercisable to the extent that exercise would cause beneficial ownership to exceed 9.99%.

Does either reporting person claim control of Pasithea (KTTAW)?

No. Neither reporting person reports sole voting or dispositive power; Heights Capital is identified as the investment manager with shared voting and dispositive power.

How many Pasithea shares were outstanding excluding warrants?

The company's quarterly report indicates 7,443,577 shares outstanding (excluding shares underlying the warrants).
Pasithea Therapeutics Corp

NASDAQ:KTTAW

KTTAW Rankings

KTTAW Latest News

KTTAW Latest SEC Filings

KTTAW Stock Data

2.71M
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI BEACH